ORIGINAL ARTICLE
Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy
Laura TestaI,VI,
, Max ManoI, Roberto Jun AraiI, Renata Colombo BonadioI,VI, Sergio V. SerranoII, Marina M Costa ZorzettoII, Susanne CrocamoIII, Oren SmaletzIV, Ruffo Freitas-JuniorV, Paulo M. HoffI,VI
Corresponding author
I Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR
II Hospital de Cancer de Barretos, Fundaçao Pio XII, Barretos, SP, BR
III Instituto Nacional do Cancer - INCA, Rio de Janeiro, RJ, BR
IV Recepta Biopharma e Hospital Israelita Albert Einstein, Sao Paulo, SP, BR
V Universidade Federal de Goias, Goiania, GO, BR
VI Oncologia D'or, Sao Paulo, SP, BR
Read
2245
Timeswas read the article
582
Total PDF
1663
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 35 | 9 | 44 |
| 2025 11 | 131 | 38 | 169 |
| 2025 10 | 88 | 13 | 101 |
| 2025 9 | 76 | 12 | 88 |
| 2025 8 | 76 | 10 | 86 |
| 2025 7 | 60 | 13 | 73 |
| 2025 6 | 65 | 6 | 71 |
| 2025 5 | 54 | 1 | 55 |
| 2025 4 | 62 | 4 | 66 |
| 2025 3 | 36 | 5 | 41 |
| 2025 2 | 58 | 3 | 61 |
| 2025 1 | 57 | 7 | 64 |
| 2024 12 | 27 | 2 | 29 |
| 2024 11 | 37 | 27 | 64 |
| 2024 10 | 47 | 40 | 87 |
| 2024 9 | 31 | 28 | 59 |
| 2024 8 | 49 | 30 | 79 |
| 2024 7 | 46 | 29 | 75 |
| 2024 6 | 37 | 20 | 57 |
| 2024 5 | 55 | 17 | 72 |
| 2024 4 | 58 | 22 | 80 |
| 2024 3 | 23 | 18 | 41 |
| 2024 2 | 22 | 19 | 41 |
| 2024 1 | 30 | 11 | 41 |
| 2023 12 | 20 | 17 | 37 |
| 2023 11 | 23 | 26 | 49 |
| 2023 10 | 26 | 36 | 62 |
| 2023 9 | 28 | 25 | 53 |
| 2023 8 | 31 | 14 | 45 |
| 2023 7 | 29 | 31 | 60 |
| 2023 6 | 44 | 13 | 57 |
| 2023 5 | 52 | 9 | 61 |
| 2023 4 | 35 | 3 | 38 |
| 2023 3 | 37 | 3 | 40 |
| 2023 2 | 49 | 2 | 51 |
| 2023 1 | 4 | 2 | 6 |
| 2022 12 | 15 | 14 | 29 |
| 2022 11 | 10 | 3 | 13 |
Show all